Publications

Coffin CS, Ramji A, Cooper CL, et. al., Epidemiologic and Clinical Features of Chronic Hepatitis B Virus Infection in 8 Canadian provinces: a Descriptive Study by The Canadian HBV Network, CMAJ Open, vol. 7, no. 4. (Article link)


Yau, A, Galorport C, Coffin CS, Ko HH, Hepatocellular Carcinoma Screening Practices in Chronic Hepatitis B among Canadian Gastroenterologists and Hepatologists: An Online Survey, Can Liv J, in press. (Article link)


Coffin CS, Fung SK, Alvarez F, Cooper CL, et. al., Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada, Can Liv J, vol 1, no. 4, p 156-217. (Article link)

 

CURRENT RESEARCH

CLINICAL TRIALS 


A Prospective Study of HBV Immunity and HBV Vaccination in Patients with NAFLD in Canada (clinicaltrials.gov)


Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity (clinicaltrials.gov)


Determination of Clinical and Molecular Properties of Hepatitis B Virus (HBV) in the Context of Concomitant Chronic Hepatitis B and Non-Alcoholic Fatty Liver Disease (NAFLD)


RESEARCH INTERESTS


Our primary interest is in advancing excellence in Hepatitis B patient care, research and education. 

Current research is focused in three main areas:

  • Understanding the natural history and epidemiology of chronic hepatitis B infection in Canada.
  • Understanding how hepatitis B patients are affected by other chronic co-infections (HIV, hepatitis delta, hepatitis C), complications of hepatitis B (liver cancer, liver transplant) and co-morbidities (e.g. non-alcoholic fatty liver disease).
  • Understanding the effect of treatment on long-term disease progression. 

Abstracts

  

Increased Controlled Attenuated Parameter (CAP) is associated with Metabolic Syndrome and Higher Liver Stiffness measurement in Chronic Hepatitis B Patients with Hepatic Steatosis enrolled in the Canadian HBV Network. Ko HH, Sebastiani G, Haylock-Jacobs S, et. al. AASLD Liver Meeting, November 2019. 


Tenofovir Alafenamide Fumarate is Effective and has Superior Renal Safety Mainly Among Stage 2 Chronic Kidney Disease (CKD): Real-World Study from the Canadian Hepatitis B Network (CanHepB). Farag M, Fung S, Tam E, et. al. AASLD Liver Meeting, November 2019.

  

Molecular characterization of hepatitis B virus and antiviral immune responses in patients with non-alcoholic fatty liver disease (NAFLD). Lucko A, Doucette K, Van Marle G, et. al. Canadian Liver Meeting, May 2019. 

  

Controlled Attenuated Parameter (CAP) is Associated with Metabolic Syndrome and Severe Liver Disease in a Multiethnic Cohort of Chronic Hepatitis B Patients with Hepatic Steatosis. Ko HH, Sebastiani G, Haylock-Jacobs S, et. al. Canadian Liver Meeting, May 2019. 

  

Impact of hepatic steatosis on biochemical and virologic response among multiethnic cohort of patients with Hepatitis B initiating antiviral therapy. Kelly E, Ramji A, Miles D, et. al. Canadian Liver Meeting, May 2019. 

  

Comparison of Demographics, Virological Status and Liver Fibrosis Assessment in HBV/HDV Coinfected Patients followed in Specialist Hepatology / Infectious Disease Clinics in Canada and King’s College Hospital, London, United Kingdom. Sadler M, Carey I, Agarwal K, et. al. Canadian Liver Meeting, May 2019.

  

Real-World Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B patients in Canada. Farag M, Fung S, Tam E, et. al. EASL, April 2019. 

  

Hepatitis B virus (HBV) B cell and T cell specific vaccine responses are reduced in high-risk obesity class patients with non-alcoholic fatty liver disease (NAFLD) and in a mice model of NAFLD compared to low-risk obesity patients and normal animals. Joshi SS, et. al. EASL, April 2019.

  

A Multisite Nationwide Descriptive Analysis of HIB-HIV Co-infection in Canada. Cooper CL, Wong D, Haylock-Jacobs S, Fung S, Barrett L, Conway B, Wong A, Ramji A, Doucette K, Coffin CS. AASLD Liver Meeting, November 2018.

  

Molecular Characterization of Hepatitis B Virus in Patients With Non-Alcoholic Fatty Liver Disease. Lucko A, Lau KCK, Joshi S, et. al. International HBV Meeting, October 2018.

  

Hepatitis D virus infection in Canada: molecular epidemiology and clinical association. Osiowy C, Swindinsky K, Haylock-Jacobs S, et. al. Global Hepatitis Summit, June 2018.

  

Hepatitis B Virus Therapy With Nucleos(t)ide Analogues Significantly Reduces Fibrosis In A ‘Real-World’ Canadian Cohort, Ramji A, Coffin CS, Ko HH, Wong A, Shaheen AA, Cooper C. Global Hepatitis Summit, June 2018. 

  

Assessment of Baseline Hepatitis B Virus (HBV) Immunity and Vaccine Responses in Prospectively Vaccinated Adults with Non-Alcoholic Fatty Liver Disease (NAFLD). Coffin CS, Jenne C, Swain MG, et. al. EASL, April 2018.

  

Burden of Comorbidities in 2138 Chronic Hepatitis B Patients Followed in Diverse Specialist Care Clinics. Coffin CS, Shaheen AA, Bailey RJ, et. al. EASL, April 2018. 

  

A Retrospective Nationwide Study on Hepatitis B Epidemiology and Genotypes; The Canadian Hepatitis B Network. Coffin CS, Ramji A, Cooper CL, et. al. AASLD, November 2017.

  

Hepatocellular Carcinoma (HCC) Screening Practices in Chronic Hepatitis B (HBV) Among Canadian Gastroenterologists and Hepatologists: An Online Survey. Yau AHL, Galoport C, Coffin CS, Ko HH. CDDW, March 2017.